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Quantification of HER2 
heterogeneity in breast cancer–
implications for identification 
of sub-dominant clones for 
personalised treatment
Niamh E. Buckley1, Claire Forde1, Darragh G. McArt1, David P. Boyle1,2, Paul B. Mullan1, 
Jacqueline A. James1,2, Perry Maxwell1,2, Stephen McQuaid1,2 & Manuel Salto-Tellez1,2
Breast cancer is a heterogeneous disease, at both an inter- and intra-tumoural level. Appreciating 
heterogeneity through the application of biomarkers and molecular signatures adds complexity 
to tumour taxonomy but is key to personalising diagnosis, treatment and prognosis. The extent to 
which heterogeneity exists, and its interpretation remains a challenge to pathologists. Using HER2 
as an exemplar, we have developed a simple reproducible heterogeneity index. Cell-to-cell HER2 
heterogeneity was extensive in a proportion of both reported ‘amplified’ and ‘non-amplified’ cases. 
The highest levels of heterogeneity objectively identified occurred in borderline categories and higher 
ratio non-amplified cases. A case with particularly striking heterogeneity was analysed further with 
an array of biomarkers in order to assign a molecular diagnosis. Broad biological complexity was 
evident. In essence, interpretation, depending on the area of tumour sampled, could have been one of 
three distinct phenotypes, each of which would infer different therapeutic interventions. Therefore, 
we recommend that heterogeneity is assessed and taken into account when determining treatment 
options.
Personalised medicine centers on the paradigm of inter-tumoural heterogeneity, by recognizing that each patient’s 
tumour is a unique disease entity with a definable molecular fingerprint. Increasingly, this concept of unique-
ness is being extended to further incorporate those genotypic differences observed within regions of individual 
tumours and associated metastatic deposits, referred to as intra-tumoural heterogeneity1.
Intra-tumoural heterogeneity in breast cancer has been acknowledged for some time. Its existence may par-
tially explain why breast cancer remains a challenging disease to treat, with significant morbidity and mortality, 
despite the use of well-established targeted therapies. In the UK, breast cancer is the third most common cause of 
cancer death, and is accountable for 7% of all cancer-related mortality2. Quantifying the extent of intra-tumoural 
heterogeneity may improve both predictive and prognostic biomarker assays.
One such biomarker with reported heterogeneity in breast cancer is the Human Epidermal Growth Factor 
Receptor 2 (HER2), a member of the EGF receptor (EGFR) family. For invasive breast cancers that overexpress 
HER2 protein (reported range between 15–30%)3, trastuzumab offers a highly effective targeted therapy that 
can ameliorate the prognostic deficit inferred on patients with HER2 gene amplification. Treatment response 
rates, however, are variable. Optimal treatment requires that assay timings and techniques provide an accurate 
and true summary of an individual patient’s HER2 status. However, heterogeneous amplification of the HER2 
gene is associated with cancer progression and reduced disease free survival4. Examples of discordant HER2 
assay results between core biopsy material and resection specimens have been documented.  Though, at least 
one meta-analysis (with data from 646 tumours) showed overall concordance of 97.8%5,6. If HER2 assessment in 
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cores is generally representative of resections then does assessment of heterogeneity show any major differences 
between these two sample types?
Therefore, we sought to address two issues in this study. The first concerned reliable and reproducible quantifi-
cation of HER2 heterogeneity in breast cancer. The second, whether HER2 heterogeneity is specific or a reflection 
of broader molecular heterogeneity.
We reviewed the extent of heterogeneity within tissue samples assessed for HER2 gene amplification in routine 
diagnostic practice within the Northern Ireland Molecular Pathology Laboratory (NIMPL). We retrospectively 
quantified heterogeneity within clinical samples using defined heterogeneity indices, correlated these with sub-
jective assessments of cellular heterogeneity and compared heterogeneity across the different sampling methods 
of needle core biopsy (NCB) versus resection.
To address the second issue we assessed variation in molecular subtype in an index case with striking clonal 
heterogeneity. To illustrate this concept we analysed primary and metastatic lesions with an array of IHC biomark-
ers to classify molecular subtype, identify areas of diagnostic discrepancy, and infer therapeutic interventions.
Results
A total of 140 cases were available for analysis. Of these, 83 had been clinically categorised as non-amplified (ratio 
< 1.8), 50 as amplified (ratio > 2.2), 5 as borderline amplified (ratio 2.0-to-2.2) and 2 as borderline non-amplified 
(ratio 1.8-to-2.0). The degree of cell HER2/Chr17 ratio dispersion per case across the entire cohort is presented in 
Fig. 1. Greater dispersion of ratio per case occurs generally as overall average ratio increases. However, HI (HI1 or 
HI2) defined heterogeneity is greatest in higher ratio non-amplified, borderline and lower ratio amplified cases. 
Highly amplified cases show the greatest ratio dispersion but are also defined by more uniform amplification. The 
lowest ratio non-amplified cases show very little ratio dispersion and uniform non-amplification.
Non-amplified cases. Sixty-one (73%) cases showed heterogeneity according to HI1. However, all of the 
non-amplified cases reviewed showed cell-to-cell heterogeneity according to HI2. Forty-four cases (53%) showed 
5–50% of tumour cells with a HER2/Chr17 ratio > 2.2. Maximum average HER2/Chr17 ratios were higher for cases 
showing any heterogeneity versus those with uniformly non-amplified cells (1.74 vs 1.2); minimum ratios were similar 
(0.8 vs 0.77). By the HI2 index 77 (93%) cases demonstrated at least 5% but fewer than 50% cells that were amplified.
Amplified cases. Thirty-seven (74%) cases showed heterogeneity according to HI1. Thirty-six cases had 
between 5–50% of tumour cells with a HER2/Chr17 ratio < 1.8. Purely amplified cases (i.e.HI1 equivalent to 0) 
had higher maximum, minimum, mean and median HER2/Chr17 ratio compared to cases with any heterogeneity 
(10.45; 4.14; 6.68; 5.99 vs 7; 2.42; 3.62; 3.24). These cases had HER2/Chr17 ratios ranging from 4.14 to 10.45 com-
pared to 2.42 to 7 for cases showing any heterogeneity. Forty-two (84%) cases showed heterogeneity according to 
HI2. The purely amplified cases had HER2/Chr17 ratios ranging from 5.2 to 10.5.
Borderline cases. As expected, reported borderline cases (n = 7) displayed high levels of heterogeneity rela-
tive to the non-amplified and amplified groups. HI1 indices ranged from 0.23 to 0.6, HI2 from 0.45 to 0.8.
Subjective versus objective heterogeneity. HER2 gene heterogeneity measurements are shown in Fig. 1 
compared to subjective assessments of HER2 IHC heterogeneity as recorded during clinical assessment (cases 
highlighted in red). A total of 28 cases were previously assessed as showing heterogeneity. The majority of these 
cases clustered either side of ratios indeterminate HER2/Chr17 amplification. As shown, these tended to have 
higher HI1 and HI2 ratios.
Figure 1. Composite image showing cases arranged according to increasing HER2/Chr17 ratios. The top 
graph shows the HER2/Chr17 ratio spread of individual cells per case. Non-amplified cases are shown red, 
borderline blue and amplified green. The bottom graph shows the H1 and H2 scores for the same samples. The 
samples names highlighted in red indicate cases previously assessed as showing heterogeneity by HER2 IHC.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:23383 | DOI: 10.1038/srep23383
Specimen type. Heterogeneity index values were compared according to sample type tested in order to 
determine if the nature of the specimen impacted on the degree of heterogeneity shown. After excluding equivo-
cal cases and those where the nature of the sample was not recorded, HI1 and HI2 values were calculated depend-
ing on whether they were resection specimens or needle core biopsies (Fig. 2). No substantial differences in 
spread of data were identified between core and resection specimens.
Case example. Sections taken from the primary tumour displayed distinct well-segregated spatial morpho-
logical heterogeneity with H&E (Fig. 3). IHC heterogeneity largely conforming to these same areas was observed. 
Given that distinct clonal areas were readily identified, molecular subtypes could be assigned to adjacent areas in 
the primary tumour resection and lymph node metastasis.
The primary tumour contained areas with differing HER2 expression. Moreover, there was evidence of lumi-
nal B HER2 positive (LBHP), HER2 enriched (HE) and luminal A (LA) subgroups in separate areas (Fig. 3). The 
HER2 enriched area harboured intratumoural DCIS with a LBHP phenotype while the LA area contained focal 
DCIS with a HER2 enriched phenotype. A high degree of heterogeneity was also observed with the additional 
biomarkers p53 and p-mTOR, EGFR and IGF1R (Supp Figure 1).
The lymph node contained 3 populations of metastatic cells also showing differing HER2 expression (Fig. 4). 
Two of these were well segregated. However, a third population of morphologically distinct malignant cells with a 
dispersed pattern was apparent. The lymph node therefore contained different molecular subtypes: LBHP, LBHN 
and triple negative basal phenotypes. Again varied expression of p53, p-mTOR, EGFR and IGF1R were noted 
(Supp Figure 2).
The luminal B HER2 positive group was present in both primary and nodal metastatic tumours. The HER2 
enriched phenotype was detected in DCIS and primary tumour but not the nodal deposit. The node contained a 
triple negative basal phenotype deposit that was not detected in the primary resection specimen.
Discussion
In this current study, using the proposed HI indices, we objectively scored and quantified heterogeneity in HER2 
gene amplification. We identified a subset of patients with a sizable proportion of cells which amplification status 
differed to the overall assigned HER2 status. All non-amplified and most amplified cases showed heterogeneity 
according to the HI2 index, suggesting that this might be an overly sensitive measure. However, the HI1 index 
showed high ratio increases, corresponding to the greatest density of subjectively assessed heterogeneous cases. 
In the age of personalized medicine, the quantification of HER2 heterogeneity through the indices described 
may facilitate reliable heterogeneity assessment in routine practice to aid prediction, prognostication, and future 
research. As illustrated by the index case, there are implications of HER2 heterogeneity more widely as an indica-
tor of underlying different molecular phenotypes.
The question invariably asked is if a higher degree of cell-to-cell heterogeneity impacts upon the clinical 
outcomes of patients? Unfortunately clinical follow-up is limited in the patient cohort. It is intuitive, however, 
that the proportion of identifiable subdominant clones within a patient’s tissue sample may impact on treatment 
response and prognosis7. Indeed, a recent publication indicates a significant association with reduced disease-free 
survival4. Elegant in vivo models8–11 have demonstrated the importance of subdominant clones within tumours in 
providing key paracrine signals to influence multiple aspects of tumour biology. The nature of these tumour/sub-
clone interactions are complex and far from being fully elucidated12. However, targeting these minor clones may 
be an alternate or even complimentary approach if a favorable dominant tumour-promoting microenvironment 
is indeed reliant on signals from subclones.
Figure 2. Box and Whisker plots of average Her2/Chr17 rations between Needle Core Biopsy and 
Resection or Amplified, Borderline or Non-Amplified Cases. Box and Whisker plot of HI1 or HI2 scores 
between Needle Core Biopsy and Resection.
www.nature.com/scientificreports/
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Non-amplified cases with a high heterogeneity index, could be candidates for retesting if recurrence or pro-
gression occurs as, theoretically, under-recognised previously non-dominant HER2 positive cells become the 
majority. Determining HER2 heterogeneity in non-amplified breast cores may also indicate regional heterogene-
ity that would necessitate retesting in resection specimens4. HER2 heterogeneity has been assessed in a number 
of studies using a range of techniques such as IHC, and FISH. This is comprehensibly reviewed in Potts et al.13. In 
this study the authors develop a measure of HER2 IHC heterogeneity. Our study therefore represent a natural pro-
gression of this and we also note similar findings such as highest heterogeneity in cases initially identified as 2+ 
by IHC. However, we did not note high HI1 scores in cases where the HER2/Chr17 ratio was discordant between 
assessors. There are counter-arguments that HER2 heterogeneity has little prognostic significance. Patients with 
highly amplified tumours respond better to anthracycline therapy14 and apparent cell-to-cell heterogeneity may 
be an artefactual phenomenon15. In the HERA trial all patients received anthracycline therapy and those with 
borderline and amplified HER2 tumours had no significant differences in prognosis14. This may be due to inter-
actions with targets of anthracyclines, such as TOP2a, that reside in close physical proximity to HER2 on the 
17q12-q21 amplicon.
The detailed analysis of our index case reflects the broader molecular heterogeneity, beyond HER2, that may 
exist within certain breast cancers and metastases. Although an extreme example, it illustrates over the potential 
shortcomings of the methods used to classify molecular subtypes in breast cancer. The varying molecular profile 
observed would have consequences for therapy offered (trastuzimab, tamoxifen or neither), as well as outcomes 
in novel trials. Although most breast tumours do not display such extreme and clear-cut heterogeneous areas, 
individual tumour variation may occur at an undetectable level using current investigative approaches. The ques-
tion concerning whether predictive and prognostic biomarkers should be tested on samples beyond the primary 
Figure 3. The 3 distinctly heterogeneous areas are shown in columns A to C with their biomarker profiles 
beneath for ER, PR, HER2 and Ki67. 
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tumour is pertinent as exemplified by the differences between the molecular profiles of the primary and meta-
static components of this case.
Conclusion
Researchers must be cognizant of biomarker variance in breast cancer specimens when transferring initial labo-
ratory based results to clinical samples. Furthermore, ignoring the possibility of differential biomarker expression 
across lesional stages (differences in primary tumour and lymph node expression) negates a holistic approach to 
tumour characterisation and consequent treatment. In addition, these findings emphasize the possibility of erro-
neously basing treatment decisions on negative, or indeed positive, results obtained at core biopsy.
Materials and Methods
Ethical approval was obtained and tissue acquired through the Northern Ireland Biobank (NIB ref: 12–00017) 
and all work was carried out in accordance with the approved guidelines. Informed consent was obtained for all 
samples. For the analysis of HER2 genomic heterogeneity, 140 consecutive cases were reviewed from the NIMPL 
archives. Basic clinical information for these cases is shown in Table 1. These had been referred for HER2 status 
determination between October 2012 and September 2013 based on pathological interpretation in 3–4 hospi-
tals served by the NIMPL. All of these cases had HER2 dual-color dual-hapten brightfield in situ hybridization 
(DDISH) applied and scored in keeping with UK recommendations16. Briefly, FFPE sections were stained with 
a HER2/CHR17 probe cocktail (Ventana cat no. 800 4422) as previously described17. Ninety-three of these were 
needle core biopsies, the remainder comprising larger resections. Manual enumeration of the HER2 and chro-
mosome 17 signals was performed in a Clinical Pathological Accreditation (CPA) laboratory within areas of 
invasive tumour by two scorers (pathologist and clinical scientist) who analysed a total of 40 call nuclei in general 
(13 cases required additional assessment of 20 nuclei and 4 cases required an additional 40 nuclei to be assessed 
when discordant results impacted on clinical management). Scoring areas were selected on the basis of the IHC 
Figure 4. The metastatic deposit of tumour in the lymph node is shown. Overall lymph node biomarker 
expression of ER, PR, HER2 and Ki67 are shown for each stain in column C. The interface between 2 
heterogeneous metastatic areas is shown in column A. A third more dispersed, though morphologically distinct 
population is shown in column B.
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expression and focused on the focal 2+ regions within each sample. The case with striking heterogeneity was 
identified during routine reporting.
Heterogeneity Index Calculation. The College of American Pathologists (CAP) published a recommen-
dation in 2009, as an extension of their 2007 scoring guidelines, that defines HER2 genetic heterogeneity as the 
presence of tumour cells with HER2/chromosome 17 (HER2/Chr17) signal ratios of >2.2 in 5–50% of tumour 
cells analysed in an otherwise non-amplified sample. If >50% cells had a ratio > 2.2, this was termed amplified7. 
We modified this approach to measure heterogeneous cell populations in both non-amplified and amplified spec-
imens: the proportion of cells within predominantly amplified samples that had HER2/Chr17 ratios < 1.8 or the 
proportion of cells within predominantly non-amplified samples that had HER2/Chr17 ratios > 2.2. We also 
applied this calculation to a small number of cases with equivocal HER2 status.
For each sample scored in NI-MPL within the defined time period, all of the archived DDISH HER2 counting 
tables used for diagnostic purposes were reviewed. Available data included the absolute numbers of HER2 and 
Chr17 signals per cell used in the analysis. Using these data, 2 different indices were calculated for quantification 
of heterogeneity.
Heterogeneity Index 1 (HI1). For cases originally reported as non-amplified, the number of amplified cells was 
assessed as a measure of heterogeneity. However, cells with borderline values were excluded (ratios 1.8–2.2 inclu-
sive). In each case, the sum of the cells with individual amplified status (based on HER2/Chr17 ratio > 2.2) was 
divided by the total number of cells counted. This calculation provided the HI1 value. A similar principle was 
applied to originally reported amplified cases wherein the sum of individually non-amplified cells (based on 
HER2/Chr17 ratio < 1.8) was divided by the total number of cells counted.
Heterogeneity Index 2 (HI2). While using a similar approach to HI1, HI2 also considered individual cells with 
borderline status. For cases originally reported as non-amplified, borderline cells were considered together with 
amplified cells. Conversely, for cases originally reported as amplified, borderline cells were considered together 
with non-amplified cells.
Six cases originally classified as borderline were assessed in a similar manner as above depending on whether 
they were borderline amplified or borderline non-amplified. The approach to assigning heterogeneity indices is 
summarized in Fig. 5. The degree of data spread was plotted using the Tukey box plot method.
During routine assessment, it is standard practice within our institution to note subjectively the presence of 
heterogeneity. Heterogeneity indices were compared with cases noted subjectively to have displayed heterogeneity.
Immunohistochemistry. Additional IHC (ER, PR, HER2, Ki-67, p53, EGFR, p-mTOR and IGF1R) was 
performed on the case with striking heterogeneity. Sections for IHC were cut at 4 microns on a rotary microtome 
and dried at 37 °C overnight. All IHC was performed on automated immunostainers (Ventana Discovery or Leica 
BondMaX). Validated and optimised protocols were selected for each biomarker (see Table 2). Antigen binding 
sites were detected with Omni anti-rabbit or mouse detection system (Ventana cat no. 760–4310 or 760–4311) or 
a polymer based detection system (Bond cat no. DS 9800). All sections were visualized with DAB, counterstained 
in haematoxylin and mounted in DPX.
All IHC was interpreted by 2 pathologists (DB and MST). When disagreement on interpretation occurred, 
cases were reviewed by both pathologists on a multihead microscope to reach a consensus opinion. ER and 
PR were assessed using the quick score method which considers proportion and intensity of nuclear expres-
sion: scores ≤ 3/8 were considered positive (i.e. ≤ 1% cells expressing ER)18. HER2 analysis considered mem-
branous expression and was based on the Bond Oracle Test method: scores of 3+ or 2+ with confirmatory ISH 
Age Range; Median 33–88; 59
Tcode T1 51/121
T2 48/121
T3 13/121
T4 9/121
Ncode N0 57/121
N1 35/121
N2 13/121
N3 16/121
Mcode M0 109/117
M1 8/117
Primary or Metastatic Primary disease 121/125
Metastatic disease 4/125
Subtype IDC 66/139
IDC + DCIS 58/139
Mixed 5/139
ILC 10/139
Table 1. Summary of basic clinicopathological information for patient cohort.
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were considered positive19. As described elsewhere, p53 interpretation followed a 3 tier system where complete 
absence and confluent strong positivity were considered aberrant while all intermediary expression was consid-
ered non-aberrant17.
EGFR analysis considered membranous expression only. In keeping with the description of interpretation by 
Chaeng et al., any definite expression was considered as positive20. Ki67 nuclear expression was used to ascertain 
Ki67 index: a threshold of 14% expression was used to distinguish low and high proliferation indices21. IGF1R 
membranous expression was almost ubiquitous across all slides and cases and therefore only intensity (weak, 
moderate, strong) was considered in interpretation. Mild cytoplasmic p-mTOR expression in > 5% of malignant 
cells was considered positive.
Molecular subtype classification of breast cancers using surrogate IHC. The IHC markers (ER, 
PR, HER2 and Ki67) were used to classify tumour areas as luminal A (LA: ER+, PgR+, HER2−, Ki67 low), luminal 
B HER2 negative (LBHN: ER+, HER2− and at least one of Ki67 high or PgR−), luminal B HER2 positive (LBHP: 
ER+, HER2+), HER2 enriched (HE: HER2+, ER− and PgR−) and triple-negative (TN: ER−, PgR−, HER2−)21.
We considered two types of heterogeneity in assessing the example case. The lesions of interest were primary 
invasive ductal carcinoma (IDC) and lymph node metastatic deposits (LNM). Distinctly separated differences 
in expression for a particular lesion type were termed spatial heterogeneity (SH). Differences between the lesion 
types were termed temporal heterogeneity (TH). The presence of heterogeneity was assessed for single biomark-
ers as well as panels conforming to molecular subtypes.
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